Anixa Biosciences, Inc.

NASDAQ:ANIX

Biotechnology

Healthcare
$2.71 +3.72%

+$0.10 today

Market cap
$94.21M
Beta
0.60
P/E (TTM)
-9.3
EPS (TTM)
-$0.30
52W Low $2.32High $5.46

Volume 0.29M

Average 0.12M

ANIX Net Income

Bottom-line profit after all expenses, interest, and taxes.

Anixa Biosciences, Inc.NASDAQ: ANIX

Net Income · Q2 FY2026 · quarter ended Apr 2026

Net income remains negative

Q2 FY2026 net income was -$2.56M, compared with -$2.79M a year earlier. Trailing-twelve-month net income was -$10.07M.

Context

  • Net income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate of -$10.17M (+6.9%) for the fiscal year ending Oct 2026, a slowdown from the +13.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterApr 2026
-$2.56M+0.4% QoQ
Last fiscal yearOct 2025
-$10.93M+13.0% YoY
LTMApr 2026
-$10.07M+17.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.4%-21.7%-30.1 pp
1 year+13.0%+6.9%-6.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(10.93M) USD
Year-over-year change
+13.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ANIX compares with its peers on the latest reported figures

  • ANIX's LTM Apr 2026 net income of -$10.07M is the 3rd highest of the 10 companies compared; the peer median is -$30.93M.
  • Its year-over-year change of +17.0% is the 4th highest of 10, against a peer median of +12.0%.
ANIX Competitors Peer median
Net Income for ANIX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGENAgenus Inc.LTM Mar 2026$64.61M +133.9%—52.2%
SPROSpero Therapeutics, Inc.LTM Mar 2026$15.24M +121.8%—27.8%
ANIXAnixa Biosciences, Inc.LTM Apr 2026-$10.07M +17.0%——
ENTXEntera Bio Ltd.LTM Mar 2026-$12.38M -22.7%——
ACTUActuate Therapeutics IncLTM Mar 2026-$21.54M +14.9%——
HURATuHURA Biosciences, Inc.LTM Mar 2026-$30.93M -50.4%——
SEERSeer, Inc.LTM Mar 2026-$70.49M +17.9%—468.7%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026-$84.93M +12.0%——
IRDOpus Genetics, Inc.LTM Mar 2026-$106.93M -82.4%—892.4%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026-$113.28M +2.6%——
Peer median (excluding ANIX) -$30.93M+12.0%—260.4%

Competitors are the stored peer set for ANIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Revenue512K0210K00
Cost of Revenue385K0161K036K
Gross Profit127K049K0(36K)
Gross Margin24.8%—23.3%——
Research & Development6.19M6.7M4.77M6.4M5.07M
Selling, General & Admin7.07M7.17M6.29M7.44M6.63M
Operating Expenses13.26M13.88M11.06M13.83M11.67M
Depreciation & Amortization59.86K42K46K37K36K
EBITDA(13.08M)(13.73M)(9.88M)(12.66M)(10.99M)
EBITDA Margin-2554.9%—-4706.7%——
Operating Income(13.14M)(13.88M)(11.01M)(13.83M)(11.7M)
Operating Margin-2565.6%—-5243.3%——
Interest Income2.32K104K1.08M1.13M673K
Interest Expense322104K000
Other Income / Expenses7.77K104K1.08M1.13M673K
Income Before Tax(13.13M)(13.77M)(9.93M)(12.7M)(11.03M)
Pre-Tax Margin-2564.0%—-4728.6%——
Income Tax Expense00000
Net Income(12.95M)(13.6M)(9.81M)(12.55M)(10.93M)
Net Margin-2528.6%—-4671.9%——
EPS (Basic)(0.45)(0.45)(0.32)(0.39)(0.34)
EPS (Diluted)(0.45)(0.45)(0.32)(0.39)(0.34)
Weighted Avg Shares28.58M30.37M30.98M31.9M32.45M
Weighted Avg Shares (Diluted)28.58M30.37M30.98M31.9M32.45M

Anixa Biosciences, Inc.

NASDAQ:ANIX

Intrinsic Alpha fair value

Locked

Current Price

$2.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.